XELJANZ (tofacitinib) - Important Safety Information from Pfizer Healthcare Ireland as approved by the HPRA

Notice type: 3rd Party Publications

Date: 30/05/2019

 

Problem Or Issue:
Important Safety Information communication from Pfizer Healthcare Ireland on XELJANZ (tofacitinib). Restriction of 10 mg twice daily use in patients who are at high risk for pulmonary embolism.
 
 Important Safety Information - XELJANZ (tofacitinib)


« Back